Related Experiment Videos

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules

T Shimokawa1, M Seike, C Soeno

  • 1Department of Internal Medicine, Division of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.

British Journal of Cancer
|February 16, 2012
PubMed
Abstract

Insights

Enzastaurin shows anti-tumor effects in lung cancer, with JAK1 pathway activity predicting sensitivity. Targeting JAK1 may enhance enzastaurin efficacy for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Enzastaurin, a protein kinase Cβ inhibitor, was investigated for its anti-cancer properties.
  • The precise mechanisms of enzastaurin in tumorigenesis are not fully understood.

Purpose of the Study:

  • To evaluate the anti-tumor effects of enzastaurin in lung cancer cell lines.
  • To identify molecular markers predictive of sensitivity to enzastaurin treatment.

Main Methods:

  • Analysis of anti-tumor effects in 22 lung cancer cell lines.
  • Gene, phosphoprotein, and microRNA profiling.
  • Development of a support vector machine algorithm for sensitivity prediction.
  • Western blotting to confirm JAK1 overexpression.

Main Results:

  • The JAK/STAT signaling pathway was identified as crucial for enzastaurin sensitivity.
  • Overexpression of JAK1 was observed in sensitive lung cancer cell lines.
  • Combined enzastaurin and JAK inhibitor treatment demonstrated synergistic anti-tumor effects.
  • JAK1-overexpressing cells showed increased sensitivity to enzastaurin.

Conclusions:

  • The JAK1 pathway serves as a potential predictive biomarker for enzastaurin therapy.
  • Further evaluation of enzastaurin is warranted in lung cancers with JAK pathway activation.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...